962 related articles for article (PubMed ID: 24494983)
1. Arginine-terminated generation 4 PAMAM dendrimer as an effective nanovector for functional siRNA delivery in vitro and in vivo.
Liu C; Liu X; Rocchi P; Qu F; Iovanna JL; Peng L
Bioconjug Chem; 2014 Mar; 25(3):521-32. PubMed ID: 24494983
[TBL] [Abstract][Full Text] [Related]
2. Dendrimer Nanovectors for SiRNA Delivery.
Liu X; Peng L
Methods Mol Biol; 2016; 1364():127-42. PubMed ID: 26472447
[TBL] [Abstract][Full Text] [Related]
3. Structurally flexible triethanolamine-core poly(amidoamine) dendrimers as effective nanovectors to deliver RNAi-based therapeutics.
Liu X; Liu C; Catapano CV; Peng L; Zhou J; Rocchi P
Biotechnol Adv; 2014; 32(4):844-52. PubMed ID: 23938269
[TBL] [Abstract][Full Text] [Related]
4. Impact of siRNA overhangs for dendrimer-mediated siRNA delivery and gene silencing.
Posocco P; Liu X; Laurini E; Marson D; Chen C; Liu C; Fermeglia M; Rocchi P; Pricl S; Peng L
Mol Pharm; 2013 Aug; 10(8):3262-73. PubMed ID: 23841848
[TBL] [Abstract][Full Text] [Related]
5. PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality.
Majoros IJ; Myc A; Thomas T; Mehta CB; Baker JR
Biomacromolecules; 2006 Feb; 7(2):572-9. PubMed ID: 16471932
[TBL] [Abstract][Full Text] [Related]
6. Efficient delivery of sticky siRNA and potent gene silencing in a prostate cancer model using a generation 5 triethanolamine-core PAMAM dendrimer.
Liu X; Liu C; Laurini E; Posocco P; Pricl S; Qu F; Rocchi P; Peng L
Mol Pharm; 2012 Mar; 9(3):470-81. PubMed ID: 22208617
[TBL] [Abstract][Full Text] [Related]
7. PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells.
Liu XX; Rocchi P; Qu FQ; Zheng SQ; Liang ZC; Gleave M; Iovanna J; Peng L
ChemMedChem; 2009 Aug; 4(8):1302-10. PubMed ID: 19533723
[TBL] [Abstract][Full Text] [Related]
8. PAMAM dendrimers for efficient siRNA delivery and potent gene silencing.
Zhou J; Wu J; Hafdi N; Behr JP; Erbacher P; Peng L
Chem Commun (Camb); 2006 Jun; (22):2362-4. PubMed ID: 16733580
[TBL] [Abstract][Full Text] [Related]
9. A Dual Targeting Dendrimer-Mediated siRNA Delivery System for Effective Gene Silencing in Cancer Therapy.
Dong Y; Yu T; Ding L; Laurini E; Huang Y; Zhang M; Weng Y; Lin S; Chen P; Marson D; Jiang Y; Giorgio S; Pricl S; Liu X; Rocchi P; Peng L
J Am Chem Soc; 2018 Nov; 140(47):16264-16274. PubMed ID: 30346764
[TBL] [Abstract][Full Text] [Related]
10. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery.
Patil ML; Zhang M; Betigeri S; Taratula O; He H; Minko T
Bioconjug Chem; 2008 Jul; 19(7):1396-403. PubMed ID: 18576676
[TBL] [Abstract][Full Text] [Related]
11. SiRNA delivery systems based on neutral cross-linked dendrimers.
Liu J; Zhou J; Luo Y
Bioconjug Chem; 2012 Feb; 23(2):174-83. PubMed ID: 22292572
[TBL] [Abstract][Full Text] [Related]
12. Poly(amidoamine)-based dendrimer/siRNA complexation studied by computer simulations: effects of pH and generation on dendrimer structure and siRNA binding.
Karatasos K; Posocco P; Laurini E; Pricl S
Macromol Biosci; 2012 Feb; 12(2):225-40. PubMed ID: 22147430
[TBL] [Abstract][Full Text] [Related]
13. In vitro gene delivery using polyamidoamine dendrimers with a trimesyl core.
Zhang XQ; Wang XL; Huang SW; Zhuo RX; Liu ZL; Mao HQ; Leong KW
Biomacromolecules; 2005; 6(1):341-50. PubMed ID: 15638538
[TBL] [Abstract][Full Text] [Related]
14. Carboxymethyl chitosan-poly(amidoamine) dendrimer core-shell nanoparticles for intracellular lysozyme delivery.
Zhang X; Zhao J; Wen Y; Zhu C; Yang J; Yao F
Carbohydr Polym; 2013 Nov; 98(2):1326-34. PubMed ID: 24053810
[TBL] [Abstract][Full Text] [Related]
15. Design considerations for PAMAM dendrimer therapeutics.
Goonewardena SN; Kratz JD; Zong H; Desai AM; Tang S; Emery S; Baker JR; Huang B
Bioorg Med Chem Lett; 2013 May; 23(10):2872-5. PubMed ID: 23583511
[TBL] [Abstract][Full Text] [Related]
16. Modulated cellular delivery of anti-VEGF siRNA (bevasiranib) by incorporating supramolecular assemblies of hydrophobically modified polyamidoamine dendrimer in stealth liposomes.
Golkar N; Samani SM; Tamaddon AM
Int J Pharm; 2016 Aug; 510(1):30-41. PubMed ID: 27291973
[TBL] [Abstract][Full Text] [Related]
17. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
18. Co-delivery of curcumin and Bcl-2 siRNA by PAMAM dendrimers for enhancement of the therapeutic efficacy in HeLa cancer cells.
Ghaffari M; Dehghan G; Baradaran B; Zarebkohan A; Mansoori B; Soleymani J; Ezzati Nazhad Dolatabadi J; Hamblin MR
Colloids Surf B Biointerfaces; 2020 Apr; 188():110762. PubMed ID: 31911391
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin.
Kirkpatrick GJ; Plumb JA; Sutcliffe OB; Flint DJ; Wheate NJ
J Inorg Biochem; 2011 Sep; 105(9):1115-22. PubMed ID: 21704583
[TBL] [Abstract][Full Text] [Related]
20. PAMAM dendrimers for siRNA delivery: computational and experimental insights.
Pavan GM; Posocco P; Tagliabue A; Maly M; Malek A; Danani A; Ragg E; Catapano CV; Pricl S
Chemistry; 2010 Jul; 16(26):7781-95. PubMed ID: 20496352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
